Peptide-Based Wnt Signal Activation Enables Scalable Production of Clinical-Grade Patient-Derived Intestinal Organoids for Regenerative Cell Therapy
Sugihara HY, Nagata S, Kawasaki S, Takahashi J, Hiraguri Y, Fukuda M, et al.
Summary
Researchers at Institute of Science Tokyo developed a GMP-compliant protocol using the Wnt-activating peptide PG-008 to grow patient-derived colonic organoids for regenerative therapy. The peptide-based approach produced remarkably pure cultures of intestinal stem cells and transit-amplifying cells, achieving 82% organoid establishment rate from 60 patients. PG-008 organoid cultures outperformed conventional recombinant WNT3A in consistency and scalability.
Clinical Significance
This work represents a major step toward clinical-grade intestinal organoid production for autologous transplantation in GI diseases. The peptide-based Wnt activation eliminates the need for expensive recombinant proteins while improving culture purity — a critical advance for bringing regenerative GI therapies from bench to bedside.
Key Findings:
- GMP-compliant protocol using PG-008 peptide for colonic organoid expansion
- 82% establishment rate across 60 patients
- PG-008 enriched LGR5+ intestinal stem cells and injury-induced regenerative ISCs
- Single-cell RNA sequencing showed PG-008 cultures were more homogeneous than WNT3A
- Collagen-cultured organoids performed comparably to Matrigel
Clinical Takeaway: Peptide-based Wnt activation is a scalable, cost-effective alternative to recombinant protein for growing patient-derived intestinal organoids — paving the way for autologous cell therapies in conditions like IBD and short bowel syndrome.
Links:
相關研究
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…